Peter Brent Sampson,Narendra Kumar B. Patel,Heinz W. Pauls,Sze-Wan Li,Grace Ng,Radoslaw Laufer,Yong Liu,Yunhui Lang
申请号：
US15738286
公开号：
US20180179221A1
申请日:
2016.06.23
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1； X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
